Gossamer Bio Reacquires Seralutinib Rights, Plans Sep 2026 FDA NDA
Gossamer Bio reacquired worldwide development and commercial rights to seralutinib from Chiesi, terminating their prior collaboration. This move consolidates global control of the program ahead of a planned September 2026 NDA submission for seralutinib in PAH, following positive FDA Pre-NDA Type B meeting minutes. Additionally, stockholders approved proposals for a convertible note exchange, reducing debt by $115.9 million, and authorized a reverse stock split. The company also reported preliminary cash, cash equivalents, and marketable securities of approximately $57 million as of June 30, 2026.
Key Highlights
- Reacquired worldwide development and commercial rights to seralutinib from Chiesi.
- Planned NDA submission for seralutinib in PAH in September 2026.
- Chiesi to pay Gossamer $5 million as reimbursement for outstanding development costs.
- Convertible note exchange reduced aggregate principal debt by approximately $115.9 million.
- Stockholders authorized the Board to effect a reverse stock split.
- Preliminary cash, cash equivalents, and marketable securities were approximately $57 million as of June 30, 2026.
Price Impact
More from GOSS
Gossamer Bio Reacquires Seralutinib Rights, Cuts Debt by $115.9M; Q2 Net Income $16.9M
Gossamer Bio Q2 Operational Loss $(26.1)M; Going Concern Warning, 46% Workforce Cut
Gossamer Bio Boosts Authorized Shares to 4B; Approves Reverse Split